Venture Investors

Venture Investors, LLC is a venture capital firm based in Madison, Wisconsin, with additional offices in Ann Arbor and Milwaukee. Established in 1982, the firm specializes in seed, early-stage, and growth-stage financing, particularly targeting the healthcare and technology sectors. It invests in a range of areas including biotechnology, diagnostics, therapeutics, and medical devices, as well as in agriculture, clean technology, and engineering. The firm is particularly focused on opportunities arising from university technology transfer, leveraging its connections with research institutions in the Midwest. Venture Investors typically makes initial investments ranging from $0.25 million to $2.5 million, with lifetime investments between $5 million and $8 million. The firm aims to be the lead investor, preferring to invest in preferred stock or debt with warrant coverage, and generally holds its investments for five to seven years until an exit occurs through an initial public offering or sale. With over $200 million in assets under management, Venture Investors is dedicated to nurturing innovative ideas that advance health and wellness.

Jim Adox

Executive Managing Director

James R. Adox

Executive Managing Director

David Arnstein

CFO and Managing Director

Scott Button

Managing Director

Jenni Le

Associate

Paul Weiss Ph.D

Managing Director

Past deals in Laser

ViaLase

Series A in 2021
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.

HistoSonics

Series C in 2020
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Eximis Surgical

Series A in 2020
Eximis Surgical, founded in 2014 and headquartered in Louisville, Colorado, specializes in developing innovative technology for laparoscopic surgery. The company has created a specimen removal device that enables surgeons to efficiently extract large specimens through small incisions. This device utilizes radio frequency (RF) energized cutting wires, which are temporarily held in a containment bag, allowing for quick and safe specimen removal. By integrating seamlessly into existing physician protocols, Eximis Surgical's technology significantly reduces the time required for specimen extraction, minimizes patient discomfort, and ensures safe surgical outcomes. Additionally, the device separates specimens into narrow strips, facilitating the creation of clean tissue segments for accurate pathology identification, thereby enhancing the overall effectiveness of minimally invasive surgery.

HistoSonics

Series C in 2019
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Eximis Surgical

Venture Round in 2018
Eximis Surgical, founded in 2014 and headquartered in Louisville, Colorado, specializes in developing innovative technology for laparoscopic surgery. The company has created a specimen removal device that enables surgeons to efficiently extract large specimens through small incisions. This device utilizes radio frequency (RF) energized cutting wires, which are temporarily held in a containment bag, allowing for quick and safe specimen removal. By integrating seamlessly into existing physician protocols, Eximis Surgical's technology significantly reduces the time required for specimen extraction, minimizes patient discomfort, and ensures safe surgical outcomes. Additionally, the device separates specimens into narrow strips, facilitating the creation of clean tissue segments for accurate pathology identification, thereby enhancing the overall effectiveness of minimally invasive surgery.

HistoSonics

Series B in 2017
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Elucent Medical

Series A in 2017
Elucent Medical LLC is focused on enhancing breast cancer treatment through innovative technology. Founded in 2014 and headquartered in Brookfield, Wisconsin, the company has developed a wireless marker tag and detection system that assists surgeons in locating breast abnormalities during surgical excision. This system aims to eliminate the need for metal clips, thereby simplifying the detection process and improving surgical outcomes. By providing tools that allow for the preservation of healthy tissue while effectively removing cancerous areas, Elucent Medical strives to make breast cancer procedures more accessible and affordable for both healthcare providers and patients.

NeuWave Medical

Series C in 2015
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

HistoSonics

Series A in 2014
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

NeuWave Medical

Series B in 2012
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

HistoSonics

Series A in 2010
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Alcon LenSx

Series B in 2009
Alcon LenSx specializes in the manufacturing of advanced surgical lasers designed for cataract surgery. The company offers a next-generation femtosecond laser system that operates inside the eye to facilitate cataract removal. This innovative technology not only focuses on cataract repair but also integrates multiple refractive surgical procedures related to the cornea and lens. Alcon LenSx is committed to enhancing surgical precision and improving patient outcomes through its cutting-edge laser solutions.

NeuWave Medical

Series A in 2008
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

IntraLase

Venture Round in 2000
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Alfalight

Series A in 2000
Alfalight specializes in the design and manufacture of high-power diode lasers tailored for industrial, defense, and telecommunications applications. The company utilizes advanced aluminum-free active region (ALFA) laser structures, which contribute to the production of laser diodes that are noted for their high reliability and efficiency. Alfalight's product range includes short-wave infrared, near-infrared, and visible lasers, alongside various laser and electro-optical systems. These innovations position Alfalight as a key player in meeting the demands of both security and telecommunication sectors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.